These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37121122)

  • 1. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
    Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
    Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.
    Tang Y; Jiang L; Tang W
    Pathol Oncol Res; 2014 Oct; 20(4):829-37. PubMed ID: 24789683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
    Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
    J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
    Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
    Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.
    Jiang Z; Yang G; Wang G; Wan J; Zhang Y; Song W; Zhang H; Ni J; Zhang H; Luo M; Wang K; Peng B
    J Exp Clin Cancer Res; 2024 Oct; 43(1):288. PubMed ID: 39425205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
    Tang Q; Pan D; Xu C; Chen L
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
    Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
    Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 15. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
    Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
    BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
    Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
    Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
    Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
    Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
    Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.